In one extension study, participants taking tirzepatide reduced their risk of progressing from prediabetes to type 2 diabetes by as much as 94% compared to placebo
Designed as a triple agonist, Retatrutide targets GLP-1, GIP, and glucagon receptorseach playing a pivotal role in weight management, energy regulation, and glucose metabolism
Retatrutide refers to a peptide known as LY3437943, which acts on three receptors: the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R)
That helps ensure that if there are nutrient gaps in your diet, your body is still getting what it needs
The FLOW trial demonstrated meaningful reductions in kidney disease progression with semaglutide. The SELECT trial showed a 20% reduction in major adverse cardiovascular events in patients with obesity and established cardiovascular disease. These are not trivial findings
This leaflet is designed for people taking an oral GLP-1 (Semaglutide) for type 2 diabetes
